Troleandomycin
Troleandomycin is a macrolide antibiotic. It was sold in Italy and Turkey. It is no longer sold in Italy as of 2018.
The drug's mode of action is to bind to the ribosome, specifically in the tunnel through which the newly formed peptide egresses, thereby halting protein synthesis.
Troleandomycin is a CYP3A4 inhibitor that may cause drug interactions.